Article

Role of Cutaneous Aquaporins in the Development of Xeroderma in Type 2 Diabetes

Nobutomo Ikarashi *, Nanaho Mizukami, Chenchen Pei, Ryogo Uchino, Izumi Fujisawa, Natsuko Fukuda, Risako Kon, Hiroyasu Sakai and Junzo Kamei *

Department of Biomolecular Pharmacology, Hoshi University, 2-4-41 Ebara, Shinagawaku, Tokyo 142-8501, Japan; cffcx065@gmail.com (N.M.); pei_chenchen@163.com (C.P.); swi10m19c_3102@mineo.jp (R.U.); aquao7wing_sky48@i.softbank.jp (I.F.); s151206@hoshi.ac.jp (N.F.); r-kon@hoshi.ac.jp (R.K.); sakai@hoshi.ac.jp (H.S.)

* Correspondence: ikarashi@hoshi.ac.jp (N.I.); kamei@hoshi.ac.jp (J.K.); Tel.: +81-3-5498-5918 (N.I.)

Abstract: Xeroderma is induced by diabetes, reducing patients’ quality of life. We aimed to clarify the roles of cutaneous water channel aquaporin-3 (AQP3) in diabetic xeroderma using type 2 diabetes model db/db mice. Blood glucose levels were unchanged in 5-week-old db/db mice compared to db/+ mice (control mice), but the pathophysiology of type 2 diabetes was confirmed in 12-week-old db/db mice. The dermal water content and AQP3 expression in 5-week-old db/db mice were almost the same as those in the control mice. On the other hand, in 12-week-old db/db mice, the dermal water content and AQP3 expression were significantly decreased. The addition of glucose to HaCaT cells had no effect on AQP3, but tumor necrosis factor-α (TNF-α) decreased the AQP3 expression level. Blood TNF-α levels or skin inflammation markers in the 12-week-old db/db mice were significantly higher than those in control mice. AQP3 levels in the skin were decreased in type 2 diabetes, and this decrease in AQP3 may be one of the causes of xeroderma. Therefore, a substance that increases AQP3 may be useful for improving xeroderma. Additionally, a decrease in skin AQP3 may be triggered by inflammation. Therefore, anti-inflammatory drugs may be effective as new therapeutic agents for diabetic xerosis.

Keywords: diabetes; aquaporin; skin; xeroderma; inflammation; TNF-α; COX-2; iNOS

1. Introduction

The number of patients with diabetes is increasing worldwide due to changes in lifestyle and social factors [1]. Polyuria and thirst occur as initial symptoms at the beginning of diabetes, after which nephropathy, retinopathy, and peripheral neuropathy develop. In clinical practice, many diabetic patients also develop skin diseases, such as skin infection, xerosis, and inflammatory skin diseases [2–4]. Among them, the most common type of skin infection, found in approximately half of diabetic patients, is mainly caused by the destruction of immunity [5,6]. Since skin infections are completely cured by the proper use of antibacterial drugs, they rarely pose a major clinical problem. On the other hand, xeroderma, a skin disease characterized by dryness of the skin due to a decrease in the dermal water content, occurs in one of four diabetic patients [2–4]. Since xeroderma is not a life-threatening disease in patients, its treatment is often neglected. However, xerosis induces itch and decreases patients’ quality of life. In addition, since xeroderma can cause other skin diseases, such as skin infections and skin gangrene, its prevention and treatment are very important. Currently, moisturizers are used as a symptomatic treatment for xeroderma. Moisturizers are effective when applied many times a day, but their therapeutic effect is not sufficient. Therefore, many scientists aim to clarify the onset mechanism of this disease to prevent and treat diabetic xerosis, but the entire process has not yet been elucidated.
Aquaporins (AQPs) were recently shown to play an important role in water transport in the body. AQP is a water channel in the cell membrane that transports water through cells based on the osmotic pressure gradient. Among AQPs, 13 subfamilies from AQP0 to AQP12 are widely distributed throughout the human body. In particular, AQP3 is highly expressed in the skin, and in AQP3-knockout mice, the dermal water content and flexibility and elasticity of the skin were reduced [7]. We previously analyzed the role of cutaneous AQP3 in the development of diabetic xerosis using streptozotocin (STZ)-induced type 1 diabetes model mice [8]. As a result of modeling, blood glucose levels were increased in STZ-treated mice, and the dermal water content and cutaneous AQP3 expression were decreased. The results showed that the expression level of AQP3 in the skin was reduced in type 1 diabetes, which may be one of the factors that cause xerodermia. However, the association between xeroderma and AQP3 expression in type 2 diabetes, which accounts for the majority of diabetes cases, remains unclear. Therefore, in this study, we clarified the overall role of cutaneous AQP3 in the development of diabetic xerosis using type 2 diabetic model mice to investigate new preventive and therapeutic methods targeting AQP3. In particular, we used \textit{db/db} mice as a model of type 2 diabetes to examine changes in the dermal water content and cutaneous AQP3 expression with the development of diabetes. Furthermore, we attempted to elucidate the mechanism by which the expression level of AQP3 in the skin changed. In the mechanism analysis, we focused on inflammation, especially tumor necrosis factor-\(\alpha\) (TNF-\(\alpha\)), based on the report that inflammation is induced in type 2 diabetes patients [9] and that TNF-\(\alpha\) regulates the expression of skin AQP3 [10].

2. Experimental Section

2.1. Materials

A glucose CII-test kit was purchased from Fujifilm Wako Chemicals Co., Ltd. (Osaka, Japan). A mouse insulin enzyme-linked immunosorbent assay (ELISA) kit was purchased from Shibayagi Co., Ltd. (Gunma, Japan). A mouse tumor necrosis factor-\(\alpha\) (TNF-\(\alpha\)) Quantikine ELISA kit was purchased from R&D Systems (Minneapolis, MN, USA). RIPA buffer was purchased from Nakarai Tesque (Kyoto, Japan). TRI reagent was purchased from Sigma–Aldrich Corp. (St. Louis, MO, USA). A high-capacity cDNA synthesis kit was purchased from Applied Biosystems (Foster City, CA, USA). SsoAdvanced Universal SYBR Green Supermix was purchased from Bio-Rad Laboratories (Hercules, CA, USA). Rabbit anti-rat AQP3 antibody was purchased from Alomone Labs (Jerusalem, Israel). Mouse anti-rabbit glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody was purchased from Chemicon International, Inc. (Temecula, CA, USA). Donkey anti-rabbit immunoglobulin G (IgG)-horseradish peroxidase (HRP) antibody was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Donkey anti-mouse IgG-HRP antibody and enhanced chemiluminescence (ECL) Prime western blotting detection reagent was purchased from GE Healthcare (Chalfont St. Giles, UK).

2.2. Animals

Five-week-old male \textit{db/db} mice and \textit{db/+} mice (control mice) were purchased from Japan SLC, Inc. (Shizuoka, Japan) and used for experiments at 5 and 12 weeks of age. The animals were housed at 24 \(\pm\) 1 \(^\circ\)C and 55 \(\pm\) 5% humidity under light from 8:00–20:00. Food (MF diet used for experimental animals, Oriental Yeast Co., Ltd., Tokyo, Japan) and water were available. In this study, we followed the guidelines for animal experiments from Hoshi University and obtained approval (approval number: 19-058) from the Animal Experiment Committee at the university.

2.3. Treatment

The backs of the mice were shaved, and the dermal water content was measured with a Tewameter (TM300, Courage & Khazaka, Cologne, Germany). Under nonfasting conditions, blood was collected under isoflurane anesthesia, and the skin (back) was
removed. The skin was instantly frozen in liquid nitrogen and then stored at −80 °C. The dermal water content was measured at a temperature of 23 ± 1 °C and 60 ± 10% humidity.

2.4. Measurements of Blood Glucose, Insulin, and TNF-α Levels

The collected blood was centrifuged (1000×g for 15 min at 4 °C) to separate the plasma. Plasma glucose, plasma insulin, and TNF-α concentrations were measured with a glucose CII test kit, mouse insulin ELISA kit, and mouse TNF-α Quantikine ELISA kit, respectively.

2.5. Cell Culture

HaCaT cells (Cell Line Service, Eppelheim, Germany) were maintained in Dulbecco’s modified Eagle medium (DMEM) containing 100 U/mL penicillin G potassium, 100 µg/mL streptomycin, and 10% fetal bovine serum.

2.6. Glucose Treatment of HaCaT Cells

The cells were plated on a culture plate and maintained in DMEM (glucose concentration: 1000 mg/L). After the cells reached subconfluence, the medium was replaced with DMEM containing glucose at 1000 mg/L or 4500 mg/L, and the cells were incubated for 24 h.

2.7. TNF-α Treatment of HaCaT Cells

The cells were plated on a culture plate and maintained in DMEM (glucose concentration: 4500 mg/L). TNF-α (1–10 µM) was added to the subconfluent cells, which were then cultured for 24 h. Ethanol (final concentration: 0.1%) was added to the control cells.

2.8. Real-Time RT-PCR

Total RNA was extracted from mouse skin or HaCaT cells using TRI reagent. cDNA was synthesized from 1 µg of RNA using a high-capacity cDNA synthesis kit. The various primers shown in Supplementary Table S1 were prepared, and real-time PCR was performed to detect the expression of each gene. Briefly, SsoAdvance Universal SYBR Green Supermix, forward primer/reverse primers for the target gene, and a cDNA solution were added to each well of a PCR plate. The fluorescence intensity was monitored with a CFX Connect real-time PCR detection system (Bio-Rad Laboratories). mRNA expression levels were normalized using mβ-actin or hGAPDH.

2.9. Preparation of Mouse Skin Samples for Western Blotting

The skin was homogenized on ice with dissection buffer (0.3 M sucrose, 25 mM imidazole, 1 mM ethylenediaminetetraacetic acid, 8.5 µM leupeptin, and 1 µM phenylmethylsulfonyl fluoride; pH 7.2) using a homogenizer. The homogenate was dispersed by an ultrasonic homogenizer and centrifuged (4000×g for 15 min at 4 °C). The obtained supernatant was centrifuged (9000×g for 10 min at 4 °C), after which the supernatant was centrifuged (200,000×g for 60 min at 4 °C). The supernatant was removed, and dissection buffer was added to the precipitate. This solution was used as a sample solution for western blotting [11].

2.10. Preparation of HaCaT Cell Samples for Western Blotting

RIPA buffer was added to HaCaT cells, and the cells were collected with a cell scraper. After homogenization on ice, the homogenate was dispersed with an ultrasonic disperser and centrifuged (15,000×g for 15 min at 4 °C). The obtained supernatant was used as a sample solution for western blotting [12].

2.11. Western Blotting

The protein concentration was measured by the bicinchoninic acid (BCA) method with bovine serum albumin (BSA) as a standard. Loading buffer (100 mM Tris, 20% glycerol,
0.004% bromophenol blue, 4% sodium dodecyl sulfate, and 10% 2-mercaptoethanol; pH 6.8) was added to the sample solution, and electrophoresis was performed on a polyacrylamide gel. The protein was transferred to a polyvinylidene difluoride membrane, and the membrane was blocked with a skim milk solution. The membrane was reacted with a primary antibody solution at room temperature. After washing, the membrane was reacted with a secondary antibody solution at room temperature. After washing, the membrane was then reacted with ECL Prime western blotting detection reagent. The membrane was photographed with a CCD camera (ImageQuant LAS500, GE Healthcare), and the band density was analyzed.

2.12. Statistical Analysis

The experimental values are shown as the mean ± standard deviation (S.D.) Student’s t-test and one-way ANOVA followed by Dunnett’s test were used to assess the statistical significance of differences.

3. Results

3.1. Body Weight, Blood Glucose Level, and Blood Insulin Level

The 5-week-old db/db mice weighed significantly more than the db/+ mice (control mice). However, the blood glucose and blood insulin levels in the two groups were almost the same. The 12-week-old db/db mice weighed approximately 48 g, which was significantly higher than the weight of the control mice (approximately 29 g). The blood glucose and blood insulin levels of the 12-week-old db/db mice were also significantly higher by approximately 2-fold and approximately 6-fold, respectively, than those of the control mice (Figure 1).

Figure 1. Body weight, blood glucose level, and blood insulin level. The body weight (A), blood glucose level (B), and blood insulin level (C) of db/+ mice and db/db mice at 5 and 12 weeks of age were measured (mean ± SD, n = 5, N.S.: not significant, ***: p < 0.001).

Although the above results indicated that the 5-week-old db/db mice did not have type 2 diabetes, the 12-week-old mice had developed type 2 diabetes with insulin resistance and obesity.

3.2. Dermal Water Content and Skin Tissue Findings

The dermal water content of the 5-week-old db/db mice was almost the same as that of the control mice. In contrast, the dermal water content of the 12-week-old db/db mice was decreased by approximately 70% compared with that of the control mice, and this difference was significant (Figure 2).

From the above, the 12-week-old db/db mice were determined to have xeroderma similar to that found in diabetic patients [2–4].
Figure 2. Dermal water content. The dermal water content was measured in db/+ and db/db mice at 5 and 12 weeks of age (mean ± S.D., n = 5, ***: p < 0.001 vs. db/+ mice).

3.3. mRNA Expression Levels of Functional Genes in the Skin

The water content of the skin is maintained by various factors, such as filaggrin, loricrin, ceramide, hyaluronic acid, and collagen [13–15]. Therefore, expression levels of the following skin functional genes were measured in the skin of db/db mice: filaggrin, loricrin, ceramide synthases (serine palmitoyltransferase 1; Sptlc1, serine palmitoyltransferase 2; Sptlc2), ceramide-degrading enzymes (alkaline ceramidase 1; Acer1, N-acylphosphosine amidohydrolase 1; Asah1), hyaluronic acid synthase 2 (Has2), a hyaluronic acid-degrading enzyme (hyaluronidase 1; Hyal1), and type I collagen (collagen type I alpha 1 chain; Col1a1, collagen type I alpha 2 chain; Col1a2).

No difference in the mRNA expression levels of filaggrin or loricrin in the skin were observed between db/db mice and the control mice. The expression levels of Sptlc1, Sptlc2, Acer1, and Asah1 were not significantly different in the 5-week-old db/db and control mice but were significantly decreased in the 12-week-old db/db mice compared with the control mice. The expression levels of Has2, Hyal1, Col1a1, and Col1a2 were significantly lower in the db/db mice than in the control mice at both 5 and 12 weeks of age (Figure 3).

Figure 3. mRNA expression levels of skin functional genes. The skin of 5-week-old and 12-week-old db/+ (white) and db/db mice (black) was removed, and the mRNA expression levels of filaggrin, loricrin, Sptlc1, Sptlc2, Acer1, Asah1, Has2, Hyal1, Col1a1, and Col1a2 were measured by real-time PCR. These genes were normalized to β-actin, and the mean value in db/+ mice was set to 100% (mean ± SD, n = 5, *: p < 0.05, **: p < 0.01, ***: p < 0.001 vs. db/+ mice).
3.4. AQP Expression in the Skin

Thirteen AQP species (from AQP0 to AQP12) are widely distributed throughout the body in mammals [16]. Among the analyzed AQPs, the expression of AQP1, AQP2, AQP3, AQP4, AQP7, and AQP9 in mouse skin was confirmed in this study. Regarding the mRNA expression levels of AQP2, AQP4, and AQP9, no difference was observed between db/db mice and control mice at either 5 weeks old or 12 weeks of age. The expression levels of AQP1 and AQP7 were significantly higher in the db/db mice than in the control mice at both 5 and 12 weeks of age. The expression level of AQP3 was not significantly different in 5-week-old db/db and control mice but was significantly lower (decreased by approximately 50%) in 12-week-old db/db mice than in 12-week-old control mice (Figure 4A).

Figure 4. AQP expression in the skin. The skin of 5-week-old and 12-week-old db/+ (white) and db/db mice (black) was removed. (A) The mRNA expression levels of AQP were measured by real-time RT-PCR, and after normalization to β-actin, the average value in db/+ mice was set to 100%. (B) AQP3 protein expression levels were analyzed by western blotting, and after normalization to GAPDH, the average value in db/+ mice was set to 100% (mean ± SD, n = 5, *: p < 0.05, **: p < 0.01, ***: p < 0.001 vs. db/+ mice).

AQP3, the most widely expressed AQP in skin, is closely related to retention of the dermal water content [17]. Therefore, we focused on AQP3 and analyzed its protein expression level. When the protein expression level of AQP3 was analyzed by western
blotting, AQP3 bands at approximately 27 kDa and 30–40 kDa were detected. It has been reported that these molecular weights correspond to nonglycosylated AQP3 (27 kDa) and glycosylated AQP3 (30–40 kDa) [18,19]. Although the stability and translocation of AQP3 to the cell membrane differ with and without glycosylation, the presence or absence of glycosylation does not affect the water permeation function of AQP3 [20–22]. In this study, the sum of the signals from these bands was analyzed and used to determine the expression level of AQP3. As a result, the protein expression level of AQP3 in 5-week-old db/db mice was similar to that in 5-week-old control mice. In contrast, the expression level of AQP3 in 12-week-old db/db mice was significantly lower than that in 12-week-old control mice (Figure 4B).

From the above results, changes throughout the development of diabetes were found to be dependent on AQP type. Furthermore, the expression level of AQP3 in the skin was revealed to be decreased at both the mRNA and protein levels with the progression of type 2 diabetes.

3.5. Effect of Glucose on AQP3 Expression in HaCaT Cells

An in vitro experiment was carried out to examine whether the decreased expression of cutaneous AQP3 observed in diabetes is caused by an increase in blood glucose levels. In particular, we analyzed the expression level of AQP3 in human HaCaT epidermal keratinocyte cells under high-glucose (4500 mg/L) and low-glucose (1000 mg/L) conditions. Even when glucose at a high concentration was added to the HaCaT cells, the mRNA expression level of AQP3 was almost the same as that measured when glucose was added at a low concentration (Figure 5A).

From the above, glucose is clearly unlikely to directly reduce the expression level of AQP3 in the skin.

![Figure 5](image_url). Effect of glucose and TNF-α on AQP3 expression in HaCaT cells. (A) HaCaT cells were cultured for 24 h in DMEM containing glucose at a low or high concentration. Total RNA was extracted from the cells, and the mRNA expression level of AQP3 was analyzed by real-time RT-PCR. After normalization to GAPDH, the average expression level in the control (low glucose) was set to 100%. (B) TNF-α was added to HaCaT cells, which were then cultured for 24 h. Total RNA was extracted from the cells, and the mRNA expression level of AQP3 was analyzed by real-time RT-PCR. The protein expression level of AQP3 was analyzed by western blotting. All data were normalized to GAPDH and are expressed with the average value of the control group set to 100% (mean ± S.D., n = 4, *: p < 0.05, **: p < 0.01, ***: p < 0.001 vs. control).
3.6. Effect of TNF-α on AQP3 Expression in HaCaT Cells

TNF-α, an inflammatory cytokine, was reported to decrease the expression level of AQP3 [10]. Therefore, we examined whether TNF-α would decrease the expression level of AQP3 in HaCaT cells.

After TNF-α was added to HaCaT cells and the cells were cultured for 24 h, the mRNA expression level of AQP3 was significantly decreased in a concentration-dependent manner compared with that of the control cells. The protein expression level of AQP3 was also significantly decreased to approximately 60% of that in the control cells due to the addition of TNF-α (Figure 5B).

From the above, TNF-α was confirmed to decrease the expression level of AQP3 in epidermal keratinocytes, as found in a previous report [10].

3.7. Blood TNF-α Concentration

TNF-α decreases the expression level of AQP3 in epidermal keratinocytes. Therefore, we next investigated the induction of systemic inflammation in 12-week-old db/db mice by measuring blood TNF-α concentration.

The blood TNF-α concentration in 5-week-old db/db mice was almost the same as that in 5-week-old control mice. In contrast, the blood TNF-α concentration in 12-week-old db/db mice was approximately 4-fold higher than that in the 12-week-old control mice (Figure 6).

From the above, systemic inflammation was revealed to be induced in 12-week-old db/db mice in which cutaneous AQP3 expression was decreased.

Figure 6. Blood TNF-α concentration. The blood TNF-α concentrations of 5-week-old and 12-week-old db/+ and db/db mice were measured with ELISA kits (mean ± S.D., n = 5, N.S.: not significant, **: p < 0.01).

3.8. mRNA Expression Levels of TNF-α, iNOS, and COX-2 in the Skin

We investigated the presence of local inflammation in the skin of db/db mice. In particular, the mRNA expression levels of TNF-α, inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2), whose expression is increased due to inflammation [23,24], were evaluated as indices of inflammation.

The mRNA expression level of TNF-α in the skin of 5-week-old db/db mice was almost the same as that of 5-week-old control mice. In contrast, the expression level of TNF-α was significantly higher (increased by approximately 4-fold) in 12-week-old db/db mice than in 12-week-old control mice. Similarly, the expression levels of iNOS and COX-2 were no different in the 5-week-old db/db and control mice, whereas these levels were significantly higher in 12-week-old db/db mice compared to 12-week-old control mice (Figure 7).
The above results show that in 12-week-old db/db mice in which decreased cutaneous AQP3 expression was observed, local inflammation was induced in the skin.

Figure 7. mRNA expression levels of TNF-α, iNOS, and COX-2 in the skin. The skin of 5-week-old and 12-week-old db/+ (white) and db/db mice (black) was removed, and the mRNA expression levels of TNF-α, iNOS, and COX-2 were measured by real-time RT-PCR. These values were normalized to β-actin, and the mean value in the db/+ mice was set to 100% (mean ± SD, n = 5, **: p < 0.01 vs. db/+ mice).

4. Discussion

Many patients with diabetes develop xerosis, but many details of the mechanism are unclear. We previously found that the expression level of AQP3 in the skin of model mice with STZ-induced type 1 diabetes was significantly decreased when the skin was dry [8]. In this study, to investigate diabetic xerosis overall, we used model db/db mice with type 2 diabetes.

When the blood glucose and blood insulin levels of the db/db mice were measured, both were similar in 5-week-old db/db and control mice, whereas in 12-week-old mice, both the blood glucose level and blood insulin level were significantly increased in the db/db mice compared to the control mice. Therefore, the development of diabetes with insulin resistance was confirmed (Figure 1). The dermal water content of the db/db mice was almost the same as that of control mice at 5 weeks of age but significantly decreased at 12 weeks of age (Figure 2). From the above, dryness of the skin was observed in db/db mice that presented with the pathology of type 2 diabetes, and this phenomenon was similar to clinical reports that diabetic patients develop xeroderma [3,4].

We investigated whether dryness of the skin during type 2 diabetes is related to the altered expression of AQP3, which plays an important role in maintaining the dermal water content [7]. The expression level of skin AQP3 in 5-week-old db/db mice was almost the same as that in control mice of the same age, but skin AQP3 expression was significantly decreased in the db/db mice compared to the control mice at 12 weeks of age (Figure 4). In addition, the decrease in AQP3, increase in blood glucose level, and decrease in dermal water content were correlated. The dermal water content was reported to be decreased in AQP3-knockout mice [7]. In addition, cutaneous AQP3 is known to change in various skin disorders [25]; for example, AQP3 is decreased in psoriasis [26] and vitiligo [27,28] and during aging [29], causing skin dryness. Furthermore, it was recently found that a decrease in skin AQP3 was involved in the dry skin observed upon treatment with an epidermal growth factor receptor (EGFR) inhibitor [30]. Therefore, xeroderma during type 2 diabetes...
may occur as a result of a decrease in cutaneous AQPs, which limits the movement of water from the vascular side of the skin to the stratum corneum, as observed in type 1 diabetes [8]. The dermal water content is maintained by various factors other than AQPs, and if the balance in these factors is broken, the dermal water content will decrease [13–15]. By analyzing the expression levels of various skin functional genes, the ceramide synthase genes Sptlc1 and Sptlc2 and ceramide-degrading enzymes Acer1 and Asah1 were found to be significantly changed at only 12 weeks old of age (Figure 3). While the amount of skin ceramide was not measured, the amount of skin ceramide in the 12-week-old db/db mice is thought to have been unchanged compared to that of the control mice since the level of all of the major enzymes responsible for ceramide synthesis and degradation were decreased. Therefore, a decrease in AQPs is more important in the development of diabetic xerosis than a decrease in the amount of ceramide.

Why did the expression level of cutaneous AQPs decrease during type 2 diabetes? First, we investigated whether an increase in blood glucose levels had been involved in the decrease in cutaneous AQPs using HaCaT cells. When HaCaT cells were treated with a high concentration of glucose, the expression level of AQPs was not changed (Figure 5A). Therefore, it is unlikely that the decreased expression of cutaneous AQPs observed during diabetes is directly related to an increase in blood glucose levels.

Patients with type 2 diabetes often suffer from obesity, which causes persistent systemic inflammation and is considered one of the causes of diabetic complications [9]. Additionally, inflammatory cytokines such as TNF-α decreased the expression level of AQPs in various cell types [10,31]. In this study, the addition of TNF-α to HaCaT cells significantly decreased the expression level of AQPs (Figure 5B). Therefore, we focused on inflammation as the mechanism of the decrease in AQPs in type 2 diabetes and performed an analysis. No change in blood TNF-α concentration or skin TNF-α, iNOS, and COX-2 mRNA expression levels was observed in 5-week-old db/db mice, which did not show a decrease in skin AQPs. In contrast, all of these parameters were significantly higher in 12-week-old db/db mice, in which decreased AQPs was observed (Figs. 6 and 7). In addition, these inflammatory markers and decreased AQPs were correlated. Therefore, systemic and local inflammation in the skin may occur during type 2 diabetes, which may decrease AQPs. In model mice with STZ-induced type 1 diabetes, in which a decrease in skin AQPs was observed, both the blood TNF-α concentration and cutaneous TNF-α expression were increased (Figure S1). Therefore, the decrease in cutaneous AQPs observed in the mice may also have been triggered by inflammation.

AQPs are distributed in not only the skin but also the large intestine [18,32] and kidney [33,34]. When the expression levels of AQPs in these organs were analyzed in 12-week-old db/db mice, a significant decrease in AQPs was observed in the colon, but AQP3 expression was significantly increased in the kidney (Figure S2). The AQP3 expression level in the colon is significantly decreased with inflammation [10,31], consistent with the results of this study. On the other hand, the expression level of AQPs in the kidney is strongly regulated by the antidiuretic hormone vasopressin, and it is known that vasopressin secretion is enhanced and renal AQP3 is increased during diabetes [35]. The results of this study strongly suggest that the regulation of AQP3 expression in the kidney during diabetes depends on vasopressin rather than inflammatory cytokines.

In this study, the expression of AQP1, AQP2, AQP4, AQP7, and AQP9 in mouse skin was confirmed, and AQP3, AQP1, and AQP7 levels were significantly higher in 12-week-old db/db mice than in control mice (Figure 4A). AQP1 is known to be expressed in melanocytes involved in melanin synthesis [36]. AQP7 is expressed in adipocytes and is involved in the transport of glycerol and water [37], similar to the function of AQP3. However, many details regarding the functions of AQP1 and AQP7 in the skin remain unclear. By clarifying the functions of these AQPs, the significance of their increased expression in type 2 diabetes will become clear in the future.
Delayed wound healing accompanied by a reduction in the dermal water content has been reported during diabetes [38,39]. Cutaneous AQP3 is involved in cell proliferation and cell migration [40,41], and delayed wound healing has been confirmed in AQP3-deficient mice [7]. It has been reported that AQP3 in the skin is decreased in STZ-induced type 1 diabetic model rats, which may cause delayed wound healing in diabetes [42]. In addition, it was clarified that the skin of pigs with experimentally induced type 1 diabetes has a lower AQP3 compared to non-diabetic pigs, that wound healing is delayed in diabetes model pigs, and that topical treatment of erythropoietin accelerates wound healing and this effect depends on the increase of AQP3 [43]. Therefore, a decrease in cutaneous AQP3 may be involved in not only xerosis but also delayed wound healing during diabetes.

The results of this study revealed that cutaneous AQP3 decreased at the onset of diabetic xerosis, which may have been triggered by inflammation. Therefore, these results suggest that not only substances that directly increase AQP3 in the skin but also anti-inflammatory drugs and anti-TNF-α antibody would be effective for the treatment and prevention of diabetic xerosis. In fact, curcumin was found to suppress the onset of skin disorders during diabetes, suggesting that this may be due to its anti-inflammatory effect [44]. A peroxisome proliferator-activated receptor γ (PPARγ) agonist used as an insulin secretagogue was found to show anti-inflammatory effects in addition to its effect in increasing AQP3 [45–49] and may be useful for diabetic xerosis. In the future, the application of these drugs in diabetic xerosis is expected.

As mentioned above, it has been reported that cutaneous AQP3 decreases during psoriasis [26]. On the other hand, metabolic syndrome including type 2 diabetes is associated with an increased risk of psoriasis [50]. From these facts, it is considered that the decrease in cutaneous AQP3 during type 2 diabetes may contribute to the increased risk of psoriasis. Therefore, the results of this research may affect various other dermatological conditions, and future development is expected.

5. Conclusions

In summary, xeroderma during type 2 diabetes may occur as a result of a decrease in cutaneous AQP3 as observed in type 1 diabetes. Therefore, a substance that increases AQP3 may be useful for improving xeroderma. Additionally, a decrease in skin AQP3 may be triggered by inflammation. Therefore, anti-inflammatory drugs may be effective as new therapeutic agents for diabetic xerosis.

Supplementary Materials: The following are available online at https://www.mdpi.com/2227-9059/9/9/2/104/s1, Table S1: mRNA primer sequences, Figure S1: Inflammatory markers in STZ-induced type 1 diabetes model mice, Figure S2: AQP3 mRNA expression levels in the colon and kidney.

Author Contributions: Conceptualization, N.I.; methodology, N.I., N.M. and C.P.; formal analysis, N.M., C.P., R.U., I.F., N.F., R.K. and H.S.; writing—original draft preparation, N.M. and C.P.; writing—review and editing, N.I., and J.K.; supervision, J.K.; project administration, N.I.; funding acquisition, N.I. and J.K. All authors have read and agreed to the published version of the manuscript.

Funding: This work was partly supported by the following grants; Grant-in Aid for Scientific Research (C) from the Japan Society for the Promotion of Science (No. 19K08783) and Kao Research Council for the Study of Healthcare Science.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of Hoshi University (approval number: 19-058, Approval date: 5/24/2019).

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.
References

1. Ogurtsova, K.; da Rocha Fernandes, J.D.; Huang, Y.; Linnenkamp, U.; Guariguata, L.; Cho, N.H.; Cavan, D.; Shaw, J.E.; Makaroff, L.E. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. *Diabetes Res. Clin. Pract.* 2017, 128, 40–50. [CrossRef] [PubMed]

2. Demirseren, D.D.; Emre, S.; Akoglu, G.; Arpacı, D.; Arman, A.; Metin, A.; Cakir, B. Relationship between skin diseases and extracutaneous complications of diabetes mellitus: Clinical analysis of 750 patients. *Am. J. Clin. Dermatol.* 2014, 15, 65–70. [CrossRef] [PubMed]

3. de Macedo, G.M.; Nunes, S.; Barreto, T. Skin disorders in diabetes mellitus: An epidemiology and physiopathology review. *Diabetol. Metab. Syndr.* 2016, 8, 63. [CrossRef] [PubMed]

4. Sakai, S.; Kikuchi, K.; Satoh, J.; Tagami, H.; Inoue, S. Functional properties of the stratum corneum in patients with diabetes mellitus: Similarities to senile scleer. *Br. J. Dermatol.* 2005, 153, 319–323. [CrossRef] [PubMed]

5. Delamaire, M.; Maugendre, D.; Moreno, M.; Le Goff, M.C.; Allannic, H.; Genetet, B. Impaired leucocyte functions in diabetic patients. *Diabet. Med.* 1997, 14, 29–34. [CrossRef] [PubMed]

6. Tater, D.; Tepaut, B.; Bercovici, J.P.; Youinou, P. Polymorphonuclear cell derangements in type I diabetes. *Horm. Metab. Res.* 1987, 19, 642–647. [CrossRef] [PubMed]

7. Hara, M.; Ma, T.; Verkman, A.S. Selectively reduced glycerol in skin of aquaporin-3-deficient mice may account for impaired skin hydration, elasticity, and barrier recovery. *J. Biol. Chem.* 2002, 277, 46616–46621. [CrossRef] [PubMed]

8. Ikarashi, N.; Mizukami, N.; Kon, R.; Kaneko, M.; Uchino, R.; Fujisawa, I.; Fukuda, N.; Sakai, H.; Kamei, J. Study of the Mechanism Underlying the Onset of Diabetic Xeroderma Focusing on an Aquaporin-3 in a Streptozotocin-Induced Diabetic Mouse Model. *Int. J. Mol. Sci.* 2019, 20, 3782. [CrossRef]

9. Volpe, C.M.O.; Villar-Delfino, P.H.; Dos Anjos, P.M.F.; Nogueira-Machado, J.A. Cellular death, reactive oxygen species (ROS) and diabetic complications. *Cell Death Dis.* 2018, 9, 119. [CrossRef] [PubMed]

10. Horie, I.; Maeda, M.; Yokoyama, S.; Hisatsune, A.; Katsuki, H.; Miyata, T.; Isohama, Y. Tumor necrosis factor-alpha decreases aquaporin-3 expression in DJM-1 keratinocytes. *Biochem. Biophys. Res. Commun.* 2009, 387, 564–568. [CrossRef] [PubMed]

11. Kon, R.; Ikarashi, N.; Hayakawa, A.; Haga, Y.; Fueki, A.; Kusunoki, Y.; Tajima, M.; Ochiai, W.; Machida, Y.; Sugiyama, K. Morphine-Induced Constipation Develops With Increased Aquaporin-3 Expression in the Colon via Increased Serotonin Secretion. *Toxicol. Sci.* 2015, 145, 337–347. [CrossRef] [PubMed]

12. Ikarashi, N.; Kon, R.; Nagoya, C.; Ishikura, A.; Sugiyama, Y.; Takahashi, J.; Sugiyama, K. Effect of Astaxanthin on the Expression and Activity of Aquaporin-3 in Skin in an In-Vitro Study. *Life 2020*, 10, 193. [CrossRef] [PubMed]

13. Baumann, L. Skin ageing and its treatment. *J. Pathol.* 2007, 211, 241–251. [CrossRef] [PubMed]

14. Rawlings, A.V.; Harding, C.R. Moisturization and skin barrier function. *Dermatol. Ther.* 2004, 17 (Suppl. 1), 43–48. [CrossRef] [PubMed]

15. Verdier-Sevrain, S.; Bonte, F. Skin hydration: A review on its molecular mechanisms. *J Cosmet. Dermatol.* 2007, 6, 75–82. [CrossRef] [PubMed]

16. Ishibashi, K.; Hara, M.; Kondo, S. Aquaporin water channels in mammals. *Clin. Exp. Nephrol.* 2009, 13, 107–117. [CrossRef] [PubMed]

17. Boury-Jamot, M.; Daraspe, J.; Bonte, F.; Perrier, E.; Schnebert, S.; Dumas, M.; Verbavatz, J.M. Skin aquaporins: Function in 11. [CrossRef] [PubMed]

18. Umenishi, F.; Narikiyo, T.; Schrier, R.W. Effect on stability, degradation, expression, and targeting of aquaporin-2 water channel protein of the renal epithelial cell. *Am. J. Physiol. Cell Physiol.* 2002, 282, F1034–F1042. [CrossRef] [PubMed]

19. Baumann, L. Skin ageing and its treatment. *J. Pathol.* 2007, 211, 241–251. [CrossRef] [PubMed]

20. Rawlings, A.V.; Harding, C.R. Moisturization and skin barrier function. *Dermatol. Ther.* 2004, 17 (Suppl. 1), 43–48. [CrossRef] [PubMed]

21. Hendriks, G.; Koudijis, M.; van Balkom, B.W.; Oorschot, V.; Klumperman, J.; Deen, P.M.; van der Sluijs, P. Glycosylation is important for cell surface expression of the water channel aquaporin-2 but is not essential for tetramerization in the endoplasmic reticulum. *J. Biol. Chem.* 2004, 279, 2975–2983. [CrossRef] [PubMed]

22. Umenishi, F.; Nariyuki, T.; Schrier, R.W. Effect on stability, degradation, expression, and targeting of aquaporin-2 water channel by hyperosmolality in renal epithelial cells. *Biochem. Biophys. Res. Commun.* 2005, 338, 1593–1599. [CrossRef] [PubMed]

23. Lee, Y.; Choi, H.K.; N’Deh, P.U.; Choi, Y.J.; Fan, M.; Kim, E.K.; Chung, K.H.; An, A.J.H. Inhibitory Effect of Centella asiatica Extract on DNCB-Induced Atopic Dermatitis in HaCaT Cells and BALB/c Mice. *Nutrients* 2020, 12, 411. [CrossRef] [PubMed]

24. Wu, D.; Yuan, P.; Ke, C.; Xiong, H.; Chen, J.; Guo, J.; Lu, M.; Ding, Y.; Fan, X.; Duan, Q.; et al. Salidroside suppresses solar ultraviolet-induced skin inflammation by targeting cyclooxygenase-2. *Onco Targets Ther.* 2016, 7, 25971–25982. [CrossRef] [PubMed]

25. Bollag, W.B.; Aitkens, L.; White, J.; Hyndman, K.A. Aquaporin-3 in the epidermis: More than skin deep. *Am. J. Physiol. Cell Physiol.* 2020, 318, C1144–C1153. [CrossRef] [PubMed]

26. Lee, Y.; Je, Y.J.; Lee, S.S.; Li, Z.J.; Choi, D.K.; Kwon, Y.B.; Sohn, K.C.; Im, M.; Seo, Y.J.; Lee, J.H. Changes in transepidermal water loss and skin hydration according to expression of aquaporin-3 in psoriasis. *Ann. Dermatol.* 2012, 24, 168–174. [CrossRef] [PubMed]

27. Kim, N.H.; Lee, A.Y. Reduced aquaporin 3 expression and survival of keratinocytes in the depigmented epidermis of vitiligo. *J. Investig. Dermatol.* 2010, 130, 2231–2239. [CrossRef]
28. Lee, A.Y. Role of keratinocytes in the development of vitiligo. Ann. Dermatol. 2012, 24, 115–125. [CrossRef]
29. Ikarashi, N.; Kon, R.; Kaneko, M.; Mizukami, N.; Kusunoki, Y.; Sugiyama, K. Relationship between Aging-Related Skin Dryness and Aquaporins. Int. J. Mol. Sci. 2017, 18, 1599. [CrossRef] [PubMed]
30. Ikarashi, N.; Kaneko, M.; Watanabe, T.; Kon, R.; Yoshino, M.; Yokoyama, T.; Tanaka, R.; Takayama, N.; Sakai, H.; Kamei, J. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib Induces Dry Skin via Decreased in Aquaporin-3 Expression. Biomolecules 2020, 10, 545. [CrossRef]
31. Ikarashi, N.; Baba, K.; Ushiki, T.; Kon, R.; Mizumura, A.; Toda, T.; Ishii, M.; Ochiai, W.; Sugiyama, K. The laxative effect of bisacodyl is attributable to decreased aquaporin-3 expression in the colon induced by increased PGE2 secretion from macrophages. Am. J. Physiol. Gastrointest. Liver Physiol. 2011, 301, G887–G895. [CrossRef] [PubMed]
32. Zheng, Y.F.; Liu, C.F.; Lai, W.F.; Xiang, Q.; Li, Z.F.; Wang, H.; Lin, N. The laxative effect of emodin is attributable to increased aquaporin 3 expression in the colon of mice and HT-29 cells. Fitoterapia 2014, 96, 25–32. [CrossRef] [PubMed]
33. Agre, P.; Nielsen, S. The aquaporin family of water channels in kidney. Nephrology 1996, 17, 409–415. [PubMed]
34. Xing, L.; Wen, J.G.; Frokaer, J.; Djurhuus, J.C.; Norregaard, R. Ortophyny of the mammalian kidney: Expression of aquaporins 1, 2, 3, and 4. World J. Pediatr. 2014, 10, 306–312. [CrossRef] [PubMed]
35. Satake, M.; Ikarashi, N.; Kagami, M.; Ogise, N.; Toda, T.; Kobayashi, Y.; Ochiai, W.; Sugiyama, K. Increases in the expression levels of aquaporin-2 and aquaporin-3 in the renal collecting tubules alleviate dehydration associated with polyuria in diabetes mellitus. Biol. Pharm. Bull. 2010, 33, 1965–1970. [CrossRef] [PubMed]
36. Osorio, G.; Zulueta-Dorado, T.; Gonzalez-Rodriguez, P.; Bernabeu-Wittel, J.; Conejo-Mir, J.; Ramirez-Lorca, R.; Echevarria, M. Expression Pattern of Aquaporin 1 and Aquaporin 3 in Melanocytic and Nonmelanocytic Skin Tumors. Am. J. Clin. Pathol. 2019, 152, 446–457. [CrossRef]
37. Verkman, A.S. More than just water channels: Unexpected cellular roles of aquaporins. J. Cell Sci. 2005, 118, 3225–3232. [CrossRef]
38. Dissemond, J.; Goos, M.; Wagner, S.N. The role of oxidative stress in the pathogenesis and therapy of chronic wounds. Hautarzt 2002, 53, 718–723. [CrossRef]
39. Soneja, A.; Drews, M.; Malinski, T. Role of nitric oxide, nitroxidative and oxidative stress in wound healing. Pharm. Rep. 2005, 57, 108–119.
40. Cao, C.; Sun, Y.; Healey, S.; Bi, Z.; Hu, G.; Wan, S.; Kouttab, N.; Chu, W.; Wan, Y. Correction: EGFR-mediated expression of aquaporin-3 is involved in human skin fibroblast migration. Biochem. J. 2017, 474, 2901–2902. [CrossRef]
41. Sebastian, R.; Chau, E.; Fillmore, P.; Matthews, J.; Price, L.A.; Sidhaye, V.; Milner, S.M. Epidermal aquaporin-3 is involved in the cutaneous wound healing. Burns 2015, 41, 843–847. [CrossRef] [PubMed]
42. Kodama, M.; Minematsu, T.; Asada, M.; Nakagami, G.; Akase, T.; Nagase, T.; Oe, M.; Mori, T.; et al. Impaired aquaporin 3 expression in reepithelialization of cutaneous wound healing in the diabetic rat. J. Investig. Dermatol. 2014, 138, 347–355. [CrossRef]
43. Hamed, S.; Ullmann, Y.; Egozi, D.; Keren, A.; Daod, E.; Anis, O.; Kabha, H.; Belokopytov, M.; Ashkar, M.; Shoﬁt, R.; et al. Topical Erythropoietin Treatment Accelerates the Healing of Cutaneous Burn Wounds in Diabetic Pigs Through an Aquaporin-3-Dependent Mechanism. Diabetes 2017, 66, 2254–2265. [CrossRef] [PubMed]
44. Kant, V.; Gopal, A.; Pathak, N.N.; Kumar, P.; Tandan, S.K.; Kumar, D. Antioxidant and anti-inﬂammatory potential of curcumin accelerated the cutaneous wound healing in streptozotocin-induced diabetic rats. Int. Immunopharmacol. 2014, 20, 322–330. [CrossRef]
45. Yokota, M.; Yahagi, S.; Tokudome, Y.; Masaki, H. Chinymyl Alcohol Suppresses PGE2 Synthesis by Human Epidermal Keratinocytes through the Activation of PPAR-gamma. Ann. Oleo Sci. 2018, 67, 455–462. [CrossRef]
46. Yoshizaki, N.; Fujii, T.; Masaki, H.; Okubo, T.; Shimada, K.; Hashizume, R. Orange peel extract, containing high levels of polymethoxyflavonoid, suppressed UVB-induced COX-2 expression and PGE2 production in HaCaT cells through PPAR-gamma activation. Exp. Dermatol. 2014, 23 (Suppl. 1), 18–22. [CrossRef]
47. Schmuth, M.; Moosbrugger-Martinz, V.; Blunder, S.; Dubrac, S. Role of PPAR, LXR, and PXR in epidermal homeostasis and inﬂammation. Biochim. Biophys. Acta 2014, 1841, 463–473. [CrossRef]
48. Mao-Qiang, M.; Fowler, A.J.; Schmuth, M.; Lau, P.; Chang, S.; Brown, B.E.; Moser, A.H.; Michalik, L.; Desvergne, B.; Wahl, W.; et al. Peroxisome-proliferator-activated receptor (PPAR)-gamma activation stimulates keratinocyte differentiation. J. Investig. Dermatol. 2004, 123, 305–312. [CrossRef]
49. Jiang, Y.J.; Kim, P.; Lu, Y.F.; Feingold, K.R. PPARgamma activators stimulate aquaporin 3 expression in keratinocytes/epidermis. Exp. Dermatol. 2011, 20, 595–599. [CrossRef]
50. Kim, H.N.; Han, K.; Park, Y.G.; Lee, J.H. Metabolic syndrome is associated with an increased risk of psoriasis: A nationwide population-based study. Metabolism 2019, 99, 19–24. [CrossRef]